Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 12/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19798980 | 1.00 | KDM2B (1.00) | KDM2BL3MBTL1MEN1KMT2APOLB | |
| SCHEMBL29576567 | 1.00 | KDM2B (1.00) | KDM2BL3MBTL1MEN1KMT2APOLB | |
| SCHEMBL17919629 | 0.86 | KDM2B (1.00) | KDM2BL3MBTL1MEN1KMT2APOLB | |
| SCHEMBL21928845 | 0.85 | L3MBTL1 (0.79) | KDM2BL3MBTL1MEN1KMT2APOLB | |
| SCHEMBL17919722 | 0.83 | KDM2B (1.00) | KDM2BMEN1KMT2AALDH1A1 | |
| SCHEMBL29577172 | 0.83 | KDM2B (1.00) | KDM2BMEN1KMT2AALDH1A1 | |
| SCHEMBL21120889 | 0.81 | KDM2B (0.71) | KDM2BMEN1KMT2AALDH1A1 | |
| SCHEMBL17913852 | 0.80 | KDM2B (1.00) | KDM2BMEN1KMT2AALDH1A1 | |
| SCHEMBL29577176 | 0.80 | KDM2B (1.00) | KDM2BMEN1KMT2AALDH1A1 | |
| SCHEMBL17919701 | 0.79 | KDM2B (1.00) | KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3242872-B1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2019-07-03 | — | — | EP | disclosed |
| US-10280149-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| WO-2016112284-A1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280149-B2 | Therapeutic compounds and uses thereof | KDM1B, KDM6B, KDM2B | KDM2B 3/4885L3MBTL1 1773/4885MEN1 2924/4885 |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, KDM6B, KDM2B | KDM2B 3/4885L3MBTL1 1773/4885MEN1 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.